Renal cell carcinoma

• An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporo … Not authorised
  2024-514496-18-00 3 "Hepatocellular carcinoma, renal cell carcinoma and different"
• An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1) Pending
  2025-522944-41-00 7 "Solid Tumours"
• A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043) Recruiting
  2025-524160-38-00 5 2026-05-12 "Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMM"
• A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizum … Recruiting
  2023-509335-60-00 1 2023-02-23 "Advanced solid tumors including (but not limited to), non-sm"
• A clinical study of different treatments for kidney cancer (MK-3475-03A) Recruiting
  2023-506838-68-00 9 2020-12-10
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-034) Recruiting
  2024-516993-31-00 5 2026-05-11 "Renal Cell Carcinoma"
• RUBIKID - Dynamic 82-Rb positron emission tomography (PET) for the grading of KIDney carcinoma Recruiting
  2024-514085-39-00 4 2026-03-03 "Kidney carcinoma"
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting
  2024-517136-21-00 5 2025-12-05 "Renal Cell Carcinoma"
• A clinical study of combination therapies in people with kidney cancer (MK-3475-03C) Recruiting
  2024-516437-12-00 9 2025-08-29 "Clear cell renal cell carcinoma"
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Recruiting
  2024-513285-19-00 1 2025-03-14 "Pancreatic Ductal Adeno Carcinoma"
• An open-label, multicentre, rollover study to evaluate safety and antineoplastic activity of OATD-02 in patients with selected advances and/ … Recruiting
  2024-513006-61-00 3 2023-08-23 "Advanced and/or metastatic solid tumours (colorectal cancer,"
• An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OA … Recruiting
  2024-510836-31-00 1 2023-02-14 "Advanced and/or metastatic solid tumours (colorectal cancer,"
• Phase 2 Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma Recruitment ended
  2023-505177-32-00 4 2024-07-31 "Intermediate-high -risk RCC, high-risk RCC who have undergon"
• Patient Preference Study of SC Pembrolizumab versus IV Pembrolizumab with hyaluronidase (MK-3475A) in multiple cancer types Recruitment ended
  2023-506017-22-00 4 2024-02-16 "Melanoma, Renal Cell Carcinoma, Non-small cell lung cancer"
• A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with I … Recruitment ended
  2024-515617-18-00 1 2022-02-14 "Advanced clear cell renal cell carcinoma (ccRCC), non-clear "
• A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in C … Recruitment ended
  2023-509604-15-00 3 2021-02-15 "Advanced Renal Cell Carcinoma"
• A clinical study of different treatments for kidney cancer (MK-3475-03B) Recruitment ended
  2023-506839-15-00 9 2020-12-21
• An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu … Recruitment ended
  2023-506184-34-00 5 2019-08-09 "Advanced Malignancies"
• A Study of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Participants with Advanced Kidney Cancer. Recruitment ended
  2023-508264-29-00 5 2019-06-11 "Advanced Renal Cell Carcinoma with Intermediate- or Poor-Ris"
• A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Adv … Recruitment ended
  2024-516477-73-00 3 2018-03-07 "Bladder cancer and kidney cancer"
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DG … Ended
  2023-503996-38-00 1 2025-05-21 "Advanced or metastatic solid tumors"
• An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporo … Ended
  2024-514496-18-01 3 2025-01-30 "Hepatocellular carcinoma, renal cell carcinoma and different"
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3 … Ended
  2023-505322-34-00 1 2024-01-08 "Advanced or metastatic solid tumors"
• A study to investigate the safety and tolerability of intravenous QEQ278 in patients with advanced solid tumors Ended
  2022-500540-38-00 1 2023-06-27 "Non-small cell lung cancer Oesophageal squamous cell carcino"

Showing 1–24 of 31 trials